Checkpoint inhibitors (anti-CTLA4 and anti-PD1-PDL1), which are already largely employed in solid oncology, have also been tested in the AML setting and may represent an interesting treatment in combination with other agents. The gene discussed is CD274; the disease is acute myeloid leukemia.